Authors’ reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?"

Ana Luísa Caires de Souza, Francisco de Assis Acurcio, Augusto Afonso Guerra Júnior, Renata Cristina Rezende Macedo do Nascimento, Brian Godman, Leonardo Maurício Diniz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Dear Editor,

We thank Dr. Malerbi for his comments regarding the systematic review [1]: “Insulin Glargine in the Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review” [2]. In particular, we thank Dr. Malerbi for pointing out the recently published ORIGIN study [3] clarifying the situation regarding insulin glargine and its neutral effects on the development of cancer following the previous observations of Hemkens et al. and Jonasson et al. [4, 5]. This will be welcomed by patients.

However, we were concerned by his comments that we “seem to have prepared their review with the primary motivation of justifying—both on administrative and juridical grounds—the denial from the government to dispense insulin analogues to those diabetic patients who need them”.
LanguageEnglish
Pages561-563
Number of pages3
JournalApplied Health Economics and Health Policy
Volume12
Issue number5
Early online date14 Aug 2014
DOIs
Publication statusPublished - 1 Oct 2014

Fingerprint

State Government
Insulin
Neoplasms
Insulin Glargine
Government
Systematic review

Keywords

  • insulin glargine
  • Brazil
  • insulin analogues

Cite this

de Souza, Ana Luísa Caires ; Acurcio, Francisco de Assis ; Guerra Júnior, Augusto Afonso ; do Nascimento, Renata Cristina Rezende Macedo ; Godman, Brian ; Diniz, Leonardo Maurício. / Authors’ reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?". In: Applied Health Economics and Health Policy. 2014 ; Vol. 12, No. 5. pp. 561-563.
@article{e9799b6c8ede41a49d4f87a73ab9b445,
title = "Authors’ reply to Dr. Malerbi: {"}Insulin glargine in a Brazilian state: should the government disinvest?{"}",
abstract = "Dear Editor,We thank Dr. Malerbi for his comments regarding the systematic review [1]: “Insulin Glargine in the Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review” [2]. In particular, we thank Dr. Malerbi for pointing out the recently published ORIGIN study [3] clarifying the situation regarding insulin glargine and its neutral effects on the development of cancer following the previous observations of Hemkens et al. and Jonasson et al. [4, 5]. This will be welcomed by patients.However, we were concerned by his comments that we “seem to have prepared their review with the primary motivation of justifying—both on administrative and juridical grounds—the denial from the government to dispense insulin analogues to those diabetic patients who need them”.",
keywords = "insulin glargine, Brazil, insulin analogues",
author = "{de Souza}, {Ana Lu{\'i}sa Caires} and Acurcio, {Francisco de Assis} and {Guerra J{\'u}nior}, {Augusto Afonso} and {do Nascimento}, {Renata Cristina Rezende Macedo} and Brian Godman and Diniz, {Leonardo Maur{\'i}cio}",
year = "2014",
month = "10",
day = "1",
doi = "10.1007/s40258-014-0113-x",
language = "English",
volume = "12",
pages = "561--563",
journal = "Applied Health Economics and Health Policy",
issn = "1175-5652",
number = "5",

}

Authors’ reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?". / de Souza, Ana Luísa Caires; Acurcio, Francisco de Assis; Guerra Júnior, Augusto Afonso ; do Nascimento, Renata Cristina Rezende Macedo; Godman, Brian; Diniz, Leonardo Maurício.

In: Applied Health Economics and Health Policy, Vol. 12, No. 5, 01.10.2014, p. 561-563.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Authors’ reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?"

AU - de Souza, Ana Luísa Caires

AU - Acurcio, Francisco de Assis

AU - Guerra Júnior, Augusto Afonso

AU - do Nascimento, Renata Cristina Rezende Macedo

AU - Godman, Brian

AU - Diniz, Leonardo Maurício

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Dear Editor,We thank Dr. Malerbi for his comments regarding the systematic review [1]: “Insulin Glargine in the Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review” [2]. In particular, we thank Dr. Malerbi for pointing out the recently published ORIGIN study [3] clarifying the situation regarding insulin glargine and its neutral effects on the development of cancer following the previous observations of Hemkens et al. and Jonasson et al. [4, 5]. This will be welcomed by patients.However, we were concerned by his comments that we “seem to have prepared their review with the primary motivation of justifying—both on administrative and juridical grounds—the denial from the government to dispense insulin analogues to those diabetic patients who need them”.

AB - Dear Editor,We thank Dr. Malerbi for his comments regarding the systematic review [1]: “Insulin Glargine in the Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review” [2]. In particular, we thank Dr. Malerbi for pointing out the recently published ORIGIN study [3] clarifying the situation regarding insulin glargine and its neutral effects on the development of cancer following the previous observations of Hemkens et al. and Jonasson et al. [4, 5]. This will be welcomed by patients.However, we were concerned by his comments that we “seem to have prepared their review with the primary motivation of justifying—both on administrative and juridical grounds—the denial from the government to dispense insulin analogues to those diabetic patients who need them”.

KW - insulin glargine

KW - Brazil

KW - insulin analogues

U2 - 10.1007/s40258-014-0113-x

DO - 10.1007/s40258-014-0113-x

M3 - Article

VL - 12

SP - 561

EP - 563

JO - Applied Health Economics and Health Policy

T2 - Applied Health Economics and Health Policy

JF - Applied Health Economics and Health Policy

SN - 1175-5652

IS - 5

ER -